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Abstract: We report a case of a 48-year-old Indian male who presented with swelling and firmness in his left upper part 
of the abdomen of one month duration with anorexia and weight loss. Initial examination revealed an intra abdominal mass 
of around 16.8x11.0x24.5cm with minimal left sided pleural effusion. A biopsy from the mass confirmed the diagnosis of 
gastrointestinal stromal tumour (GISTs) as supported by immmunohistochemistry results which showed strong positivity for 
c-kit while stains for smooth muscle actin, desmin, myoglobin, S100 Protein and cytokerstin remained negative. The patient 
was not suitable for surgical intervention in view of advanced tumor, and Imatinib Mesylate 400mg daily was started with 
the aim of making the tumor operable. Such therapy lasted for twenty months and was tolerated well by the patient. It 
then resulted in gradual tumor regression, following which the patient underwent successful tumor resection. Post surgical 
resection patient had no radiological evidence of intra abdominal tumor but mild left sided pleural effusion with left lower 
lobe atelectasis. The patient had uneventful post operative recovery and he is currently on Imatinib mesylate and tolerating 
treatment well with mild skin rash. The experience with preoperative imatinib on surgical resection rates and post operative 
outcomes is limited especially with primary locally advanced GISTs. In our case successful surgical resection was possible 
for a huge locally advanced GIST with unusually prolonged treatment of twenty months with imatinib preoperatively. 
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Introduction 
Gastrointestinal stromal tumors (GISTs) are considered 
the most common mesenchymal tumors of gastrointestinal 
tract (GI), arising from the  mesenchymal stem cells that 
latter on differentiate in to pacemaker cells of GI tract 
(cells of Cajal), responsible for peristaltic activity in GI 
tract. Demonstration of KIT tyrosine kinase activity in 
GIST tumorigenesis has identified a target for therapy. 
Imatinib is an inhibitor of mutated activated isoform of KIT 
tyrosine kinase [1].    
 
The literature about GISTs remains confusing because 
tumor classification and terminology are being continually 
refined. Furthermore, the exact definition of GISTs varies 
among authors. Some use the term to describe any GI 
submucosal mesenchymal tumor that is not myogenic 
(e.g, leiomyosarcoma) or neurogenic (eg, schwannoma) in 
origin. Others are more restrictive and use the term when 
specifically referring [2]. 
 
Histologically, the number of mitotic figures is used to 
decide on grading of GISTs, but no standard exists for 
classification. In general, tumors with less than 1 mitotic 
figure per 50HPFs are considered benign, while 1-5 per 
10HPFs as potential malignant and more than 5 per 
10HPFs as malignant. Clinical presentation ranges from 
asymptomatic tumors being discovered during surgery for 
other indication to tumors as big as 30cm [3]. 
 
Before the availability of imatinib complete surgical 
resection of metastatic or recurrent GIST was achieved in 
only one third of patients with overall five year survival 
approximately 20% [2]. Current trend is to use imatinib 
for locally advanced metastatic or recurrent GIST as first 
line and then consider surgical resection for residual 
disease. Use of imatinib preoperatively to make tumor 
operable has variable response rates. In our case, the 
unusually prolonged treatment for twenty months resulted 
in significant tumor reduction to allow surgical resection. 
 
 
Case report 
A 48-year-old Indian male presented with history of 
swelling and firmness in his left upper part of abdomen of 
one month duration associated with lethargy and loss of 
appetite. The swelling gradually enlarged over the period 
of time and involved left hypochondriac and lumbar 
regions before presentation. He denied any bowel 
symptoms but gradual weight loss was noted, which was 
not documented by the patient. 
 
On Examination he was mildly pale but neither jaundice 
nor lymphadenopathy were noticed, abdominal 
examination revealed a huge mass extending from left 
hypochondriac region down to left iliac fossa and up to 
umbilicus medially but no ascites detected. 
Workup showed Hemoglobin of 9.4gm/dl but renal and 
liver function tests were within normal range. 
 
A CT scan abdomen and thorax was ordered which 
showed a large fairly well circumscribed heterogeneously 
enhancing mass in the left side of the abdomen extending 
up to the left iliac fossa measuring 16.8x11.0x24.5cm. The 
mass was displacing the stomach to the right side and 
pancreas posteriorly, liver, spleen and kidneys appeared 
normal (Fig. 1). A differential diagnosis of 
leiomyosarcoma, fibrous histiocytoma and fibrosarcoma 
was suggested. 
 
Biopsy from the mass suggested the diagnosis of 
malignant gastrointestinal stromal tumor as supported by 
high expression for c-kit, vimentin and negative staining 
for smooth muscle actin, desmin, myoglobin, S100 and 
cytokeratin on immunohistochemistry. 
 
Because the patient was not keen for surgical 
intervention, he was given a trial of neoadjuvent imatinib 
mesylate at a dose of 400mg daily to be continued till 
tumor became operable. 
 
Therapy was continued for twenty months and patient 
reassessment was done in between for tumor response 
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with repeated C.T. scan every two to three months. Only 
after twenty months of therapy the tumor was reduced to 
15.2x7x23cm, which was then considered for surgical 
excision. 
 
The patient tolerated therapy well and apart from mild 
desquamating rash no serious side effect was noted, and 
he underwent repeated liver function tests throughout the 
study period. 
 
 
Figure 1 Intra abdominal tumor at presentation 
 
A surgical attempt was made after the patient 
consented to the procedure and the tumor was 
successfully removed. The patient had an uneventful 
surgical outcome and repeated C.T. scan post operatively 
did not show any residual tumor (Fig. 2). The patient is 
currently followed up with no symptoms at present and he 
is tumor-free. 
 
 
Figure 2 Successful surgical resection of intra abdominal tumor 
post imatinib treatment. 
 
Discussion 
So far surgery has been the standard treatment for 
primary resectable GISTs [4]. We have limited data on the 
role of neoadjuvent imatinib mesylate for the treatment of 
GISTs and most evidence comes from anecdotal cases or 
case series demonstrating benefits of neoadjuvent 
imatinib mesylate [5-6]. Ongoing trials by radiation 
therapy and oncology group (RTOG-S-0132) [7] and M.D 
Anderson [8]. are evaluating the role of preoperative 
imatinib on the treatment of localized or metastatic GISTs. 
 
Patients treated with preoperative imatinib tend to have 
better median disease free survival compared to 
previously reported eighteen month-survival before the 
availability of imatinib [9].         
    
The role of tumor debulking is not established in GISTs. 
The median postoperative survival has ranged from two to 
twenty months after tumor resection in this situation.  
 
Although complete surgical resection is possible in 
patients receiving preoperative (Neoadjuvent) imatinib for 
recurrent or metastatic GISTs but optimal timing for 
surgical resection is not known. In view of encouraging 
results with preoperative imatinib many centres are now 
adopting the strategy. 
 
Scaife et al. studied 126 patients, of these, 17 have 
subsequently undergone surgical resection after a median 
of 10 months of treatment with imatinib. Based on 
computed tomographic (CT) scanning, 1 (6%) patient had 
evidence of a complete tumor response, 12 (70%) 
patients had a partial response, 3 (24%) patients had 
stable disease, and 1 (6%) patient had progressive 
disease [10].        
 
As per ESMO (European Society for Medical Oncology) 
recommendation, neoadjuvent imatinib is advised for 
cytoreduction to decrease tumor bleeding and risk of 
tumor rupture, a usual 6-12 months period of neoadjuvent 
therapy is advised. Standard treatment for GIST is 
complete surgical resection, without dissection of clinically 
negative nodes. Given the efficacy of imatinib in the 
disease, adjuvant treatment with the drug has been 
studied but so far no definitive evidence is available to 
recommend the drug in this setting. In locally advanced 
inoperable tumors and metastatic tumors, imatinib is the 
standard treatment, this applies to metastatic patients 
who have been completely free of disease by virtue of 
previous surgery and discovered unexpectedly. 
 
 The standard dose of imatinib is 400mg daily. Patients 
carrying mutation in exon 9 KIT fare better with a higher 
dose of up to 800mg daily, which is therefore a standard 
treatment in this subgroup. Close monitoring of tumor 
response is needed since the risk of secondary progression 
persists. Complete excision of residual has been related to 
good prognosis but the possibility of selection bias cannot 
be ruled out, therefore surgery in metastatic tumors 
responding to imatinib remains investigational. The 
standard approach in case of tumor progression is to 
increase the dose of imatinib up to 800mg daily especially 
with tumors carrying exon 9 KIT mutations. Patients who 
are non-compliant to treatment should be ruled out [11]. 
 
So far, the reported usual median time for treatment 
response in locally advanced tumor is up to 6 to 12 
months, neoadjuvent therapy with imatinib should be 
attempted in locally advanced GISTs [11]. 
 
The reason for tumor response in our case was likely 
due to high positivity for c-kit tyrosine kinase. This case 
reinforces the evolving role of neoadjuvent therapy for 
locally advanced or metastatic GISTs. Preoperative 
treatment should be continued if no disease progression is 
noted. Tumor density change on CT scan or MRI scans is 
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an indicator of tumor response, however PET scan is a 
better tool for tumor response assessment. Tumor size 
may not decrease although tumor may be responding 
[11]. In our case it took twenty months of therapy with 
imatinib to make tumor excision possible.  
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